Multimodal digital assessment for myasthenia gravis.
Official title: Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis
Run by Huashan Hospital · NCT07146425 · Data updated 2026-11-12
This project will try a multimodal digital system using facial and eye-movement videos, speech and limb motion recordings, and physiological sensors to see if it can measure symptom severity in adults with myasthenia gravis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 180 (estimated) |
| Sponsor | Huashan Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | August 31, 2023 |
| Main results expected | December 2025 |
| Study ends | December 2025 |
| Registry record updated | August 28, 2025 |
| Trial ID | NCT07146425 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal participants are adults (≥18) with a confirmed MG diagnosis (MGFA class I–IV or asymptomatic after treatment) who can provide consent and cooperate with digital testing, plus age-matched healthy volunteers as controls.
✕Probably not a fit
Patients in myasthenic crisis (MGFA V), those with severe cardiopulmonary disease, significant psychiatric or cognitive impairment, or other unstable medical conditions are excluded and unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center, exploratory observational study at Huashan Hospital (Fudan University) will collect synchronized multimodal digital phenotypic data from adults with myasthenia gravis and matched healthy controls. Data collected will include physiological signals, facial and eye-movement videos, speech and limb movement recordings, clinical scales, and quality-of-life measures. Researchers will use descriptive subgroup analyses and machine learning to identify features linked to MG severity, then build and prospectively validate a digital evaluation model. The team will also develop a patient-facing remote evaluation system based on the model to support diagnosis, monitoring, and rehabilitation in real-world settings.
Why it matters
Potential benefit: If successful, the model could provide an objective, precise, and remote way to track MG symptoms and treatment response, improving clinical decision-making and patient self-monitoring.
How similar studies have gone: Multimodal digital phenotyping and AI-derived models have shown promise in other neurological disorders, but applying a comprehensive multimodal digital model specifically to myasthenia gravis is relatively novel and remains exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: For Patients with MG * Patients have a confirmed diagnosis of myasthenia gravis and be over 18 years old. * Patients have the clinical classification of Myasthenia Gravis Foundation of America (MGFA) within I-IV, or be asymptomatic after treatment. * Patients must sign the informed consent form and the privacy confidentiality agreement. For Healthy Participants * Age group matched with MG participants Exclusion Criteria: For Patients with MG * Patients are in the crisis stage of myasthenia gravis (MGFA class V) and unable to cooperate with scoring. * Patients are with severe cardiopulmonary diseases and unable to cooperate with the scoring. * Patients with any psychiatric disorder or cognitive dysfunction that, in the investigator's judgment, may interfere with their participation in the study. * Patients with any other unspecified unstable medical condition.
Where it's running
-
Huashan Hospital, affiliated to Fudan University
Shanghai, China Recruiting
Study contacts
- Principal investigator: Chongbo Zhao, Ph.D. — Huashan Hospital
- Study coordinator: Yanan Miao, Ph.D.
- Email: himed@fudan.edu.cn
- Phone: 0086-021-52888780
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
MG patient registry to track long-term experiences and treatment patterns
This registry collects information from adults with myasthenia gravis to see how symptoms and quality of life change over time and how treatments relate to those changes.
-
Ublituximab maintenance after efgartigimod response in myasthenia gravis
This study tests whether giving ublituximab as maintenance after a positive response to efgartigimod helps adults with myasthenia gravis.
-
Pregnant Women with Neuroimmune Diseases: A long-term follow-up study
This study follows women with neuroimmune diseases and healthy controls through pregnancy and up to ten years to see how pregnancy affects disease activity and outcomes for both mother and baby.
-
Early ravulizumab for adults with myasthenic crisis in the ICU
This project will test whether giving ravulizumab early to adults with AChR-positive generalized myasthenia gravis who are in the ICU for a myasthenic crisis helps speed recovery.
-
KITE-363 treatment for relapsed or refractory autoimmune neurologic diseases
This study will test whether KITE-363 is safe and can help people with relapsed or treatment-resistant autoimmune neurologic diseases such as MS, CIDP, and myasthenia gravis.
-
ADAPT Forward master protocol testing multiple regimens for generalized myasthenia gravis
This platform tests several drug regimens, including efgartigimod IV and empasiprubart IV, in adults with generalized myasthenia gravis to find safer and more effective treatment combinations.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.